CollPlant and United Therapeutics sign major licensing agreement for bioprinted lungs Bioprinting
Biotech companies CollPlant and United Therapeutics Corporation have signed an agreement for the licensing, development and commercialization of 3D bioprinted lungs for transplant. The companies will leverage their respective specializations: CollPlant will offer its proprietary recombinant human collagen (rhCollagen) and bioink technology, while United Therapeutics will use its expertise in regenerative medicine and organ manufacturing.